<?xml version="1.0" encoding="UTF-8"?>
<fig id="Fig1">
 <label>Fig. 1</label>
 <caption>
  <p>Schematic representation of the immunomodulators’ site of action. Hydroxychloroquine, azithromycin, statins, RAASi and their combinations have not been reliably shown to be of benefit in hospitalized patients with COVID-19, and therefore are represented here to define a potential pathophysiological target for therapy. This should not be seen as endorsement for use of such agents. The use of hydroxychloroquine and azithromycin in COVID-19 patients may be associated with harm. Whether such agents are beneficial in other stages of infection remains a matter of study.   Created with biorender.com. 
   <italic>Ang II</italic> angiotensin II, 
   <italic>GM-CSF</italic> granulocyte–macrophage colony-stimulating factor, 
   <italic>IFN</italic> interferon, 
   <italic>IL</italic> interleukin, 
   <italic>IL-6R</italic> interleukin-6 receptor, 
   <italic>IVIG</italic> intravenous immunoglobulin, 
   <italic>JAK</italic> Janus kinase, 
   <italic>JAK-STAT</italic> Janus kinase-signal transducer and activator of transcription, 
   <italic>MIP-1α</italic> macrophage inflammatory protein 1-α, 
   <italic>MyD88</italic> myeloid differentiation primary response 88, 
   <italic>NF-κB</italic> nuclear factor-κB, 
   <italic>RAAS</italic> renin–angiotensin–aldosterone system, 
   <italic>rhuGM-CSF</italic> recombinant human granulocyte–macrophage colony-stimulating factor, 
   <italic>sIL-6R</italic> soluble IL-6 receptor, 
   <italic>TLR</italic> toll-like receptor, 
   <italic>TNF</italic> tumor necrosis factor reserve
  </p>
 </caption>
 <graphic xlink:href="40265_2020_1367_Fig1_HTML" id="MO1" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
